Brokerages predict that Catabasis Pharmaceuticals Inc (NASDAQ:CATB) will post ($0.16) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Catabasis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.22). Catabasis Pharmaceuticals reported earnings of ($0.31) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 48.4%. The business is expected to report its next earnings results on Thursday, November 8th.

According to Zacks, analysts expect that Catabasis Pharmaceuticals will report full-year earnings of ($0.75) per share for the current financial year, with EPS estimates ranging from ($0.95) to ($0.54). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.67) per share, with EPS estimates ranging from ($0.95) to ($0.38). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Catabasis Pharmaceuticals.

Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its quarterly earnings results on Friday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03.

A number of analysts have commented on CATB shares. Zacks Investment Research raised Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Tuesday, August 14th. ValuEngine raised Catabasis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Citigroup decreased their price objective on Catabasis Pharmaceuticals from $2.50 to $1.50 and set a “buy” rating for the company in a report on Friday, August 10th. Finally, Wedbush set a $3.00 price objective on Catabasis Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $3.54.

CATB traded down $0.01 during midday trading on Wednesday, reaching $0.77. 108,927 shares of the company were exchanged, compared to its average volume of 823,611. The firm has a market capitalization of $50.25 million, a P/E ratio of -0.61 and a beta of 0.59. Catabasis Pharmaceuticals has a one year low of $0.61 and a one year high of $3.78.

Institutional investors and hedge funds have recently modified their holdings of the business. Deutsche Bank AG bought a new stake in Catabasis Pharmaceuticals during the 4th quarter worth approximately $335,000. Stonepine Capital Management LLC bought a new stake in Catabasis Pharmaceuticals during the 2nd quarter worth approximately $2,302,000. Finally, Federated Investors Inc. PA bought a new stake in Catabasis Pharmaceuticals during the 2nd quarter worth approximately $10,006,000. 41.21% of the stock is owned by hedge funds and other institutional investors.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases.

See Also: What do I need to know about analyst ratings?

Get a free copy of the Zacks research report on Catabasis Pharmaceuticals (CATB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.